Research programme: placenta-derived stem cell therapies - Celgene

Drug Profile

Research programme: placenta-derived stem cell therapies - Celgene

Alternative Names: Sickle cell anaemia cell therapy - Celgene

Latest Information Update: 26 Jun 2013

Price : $50

At a glance

  • Originator Celgene Corporation
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements; Haematopoiesis modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Sickle cell anaemia

Most Recent Events

  • 26 Jun 2013 No development reported - Preclinical for Sickle cell anaemia in USA (unspecified route)
  • 24 May 2006 This programme is still in active development
  • 31 Dec 2004 Preclinical trials in Sickle cell anaemia in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top